SREBF1 and Hepatic steatosis: Although LXR agonists were advanced to clinical development for the treatment of AS, unfortunately, in the liver, LXR agonists activate lipogenesis by upregulation of sterol regulatory element binding transcription factor 1c (SREBP-1c), and thereby substantially induce fatty liver and hyperglyceridemia [11].